. 2015 Jul 20;17(11):848–854. doi: 10.1111/jch.12622

Table 3.

Adjusted Regression Coefficients for Users of TD Monotherapy Compared With Users of Non‐TDs or ACE Inhibitors or ARBs

Outcomes	Drug Groups: TD vs Non‐TD				Drug Groups: TD vs ACE Inhibitors/ARBs
Outcomes	Adjusted Coefficient	SE	P Value	95% CI	Adjusted Coefficient	SE	P Value	95% CI
Central SBP	0.445^a	1.047	.007	−1.606 to 2.496	0.265^a	1.061	.005	−1.814 to 2.344
Central DBP	−0.954^a	1.161	<.001	−3.229 to 1.321	−1.405^b	1.201	<.001	−3.759 to 0.949
Central PP	−0.278^a	1.065	.005	−1.810 to 2.366	−0.035^b	1.077	.003	−2.077 to 2.146
MAP	−0.939^a	1.333	.002	−3.552 to 1.674	−1.519^b	1.370	.001	−4.205 to 1.167
Central AIx	−0.254^b	0.956	<.001	−2.127 to 1.619	−0.308^a	0.961	<.001	−2.191 to 1.575

Abbreviations: AIx, augmentation index; DBP, diastolic blood pressure; MAP, mean arterial pressure; PP, pulse pressure; SE, standard error; SBP, systolic blood pressure. Non‐thiazide diuretic Non‐(TD) antihypertensive includes angiotensin‐converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), β‐blockers, calcium channel blockers, and other antihypertensive agents (diuretics [other than thiazide‐type], antiadrenergic agents, and agents acting on the renin‐angiotensin system [excluding ACE inhibitors and ARBs]). In all models, TD was the reference category. ^aAdjusted for sex, age, quadratic age, body mass index (BMI), quadratic BMI, International Physical Activity Questionnaire, hypercholesterolemia, comorbidities, smoking, alcohol intake, heart rate, and high blood pressure onset date. ^bAdjusted for all previous variables and height instead of BMI.